Tolera Therapeutics Announces Appointment of Linda C. Hogan as Vice President, Business Development

KALAMAZOO, Mich., Oct. 1, 2012 /PRNewswire/ -- Tolera Therapeutics, Inc., a privately held biotechnology company focused on the development of immunotherapeutics directed at the transplantation, autoimmune and oncology markets announced today the appointment of Linda C. Hogan as Vice President of Business Development.

Linda has over 25 years of experience in the healthcare industry, having served as Vice President of Global Business Development for Aventis in addition to various roles in medical affairs, strategic planning and finance, new business market intelligence, and licensing for its predecessor companies of Marion Laboratories, Marion Merrell Dow, and Hoechst Marion Roussel. In addition to founding LLH Associates, a business development and strategic advisory consultancy, Linda was also Vice President of Business Development for Clearview Projects and has experience in venture capital as an Executive in Residence at Care Capital, LLC.

"Linda has extensive partnering and transaction skills and we are very pleased to add her to the Tolera team to help advance our partnering activities," commented President and CEO, John Puisis.

"I am excited to join Tolera Therapeutics and look forward to assisting with strategic and transactional activities at a key time in the company's history.  It is a privilege to work with a group focused on bringing targeted and safer therapies to transplant patients as well as those suffering from other immunological diseases," said Ms. Hogan.

Prior to joining the pharmaceutical industry, Linda was Assistant Professor of Pharmacy Practice and Director of Drug Information Services for the University of Kansas (KU) School of Pharmacy and Kansas University Medical Center. She received an MS in Hospital Pharmacy from KU and holds an MBA from Rockhurst College and a CLP from the Licensing Executive Society.

About Tolera Therapeutics:  Tolera Therapeutics is a Kalamazoo, Michigan based biotechnology company.  Primary investors in the company include the SWMF Life Sciences Fund, Triathlon Medical Venture Partners, Hopen Life Sciences Fund and the Michigan Economic Development Corporation.  Building upon research done at the University of Kentucky and the Cleveland Clinic, Tolera Therapeutics is developing and commercializing therapies for the immune modulation market with the goal of addressing unmet medical needs with safer, more targeted solutions to reduce the risk of serious and toxic side effects often associated with immunotherapy.  The company is focusing on commercializing its therapeutic monoclonal antibody technology for the transplantation market.  Additional information concerning the company and its technology can be found on its website www.tolera.com.  

SOURCE Tolera Therapeutics, Inc.